March - 2013
| Previous Next | Showing Journal 11 of 13 |
A Phase 2 Randomized, Double-Blind, Placebo– Controlled Study of the Safety and Efficacy of Talactoferrin in Patients With Severe Sepsisthe TLF LF-0801 Investigator Group Crit Care Med, 2013, 41:706-716 This page is only available to Crit-IQ subscribers. To view the rest of this review and gain access to our vast array of critical care teaching tools including podcasts, vodcasts, modules, exam preparation tools, teaching aids and much more, login here, or Become a Member to register |
March |
Previous Comments
| Lets hope this doesn't lead us down another Activated Protein C pathway... | |
| Gordon West-12 Mar, 2013 01:02:29 PM | |
Comment
This phase 2 RCT looks at the effect of talactoferrin - a recombinant lactoferrin, a glycoprotein with anti-infective and anti-inflammatory properties found in secretions and immune cells - delivered enterally in severe sepsis. The theory is that it would reduce translocation of bacteria...